Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025)
Zentalis Pharmaceuticals' quarterly Return on Sales came in at 0.06% in Q3 2025, down 1.0% year-on-year from 0.06% in Q3 2024, and up 8.27% quarter-over-quarter from 0.06% in Q2 2025.
Zentalis Pharmaceuticals has reported Return on Sales for 2 years, with the latest figure at 0.06% in Q3 2025.
- For the quarter ending Q3 2025, Return on Sales fell 1.0% year-over-year to 0.06%; the trailing twelve-month figure through Sep 2025 stood at 0.06% (down 1.0% YoY), and the FY2024 full-year result was 0.02%, changed N/A from the prior year.
- Return on Sales for Q3 2025 stood at 0.06%, up from 0.06% in the prior quarter.
- The five-year high for Return on Sales was 0.0% in Q1 2024, with the low at 0.08% in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.00% |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.06% |
| Jun 30, 2025 | -0.06% |
| Mar 31, 2025 | -0.08% |
| Dec 31, 2024 | -0.02% |
| Sep 30, 2024 | -0.04% |
| Jun 30, 2024 | -0.05% |
| Mar 31, 2024 | 0.00% |